Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal CPB and Anticoagulation in Obese Patients
NCT03302195Recruiting
- Sponsor
- Université Laval
- Start
- Aug 2015
- Primary completion
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Randomised trial of heparin in cardiac disease (4 arms), sponsored by Université Laval. Primary endpoint: Allogeneic transfusions of red blood cells at 7 days. Started Aug 2015; status: recruiting.
02
Drugs
heparin
03
Conditions
cardiac disease
Beyond the preview
Go deeper on NCT03302195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03302195.